Humanized anti-human CD132 monoclonal antibody and its application
By developing humanized anti-human CD132 monoclonal antibodies h2D4H4K12 and h5H10H6K4, the activity of γ-chain cytokines such as IL-21 and IL-4 was solved, and the problem of insufficient targeting B cells in the prior art was significantly reduced. Urine protein and plasma anti-dsDNA levels in SLE mice improved the therapeutic effect and reduced the immunogenicity of the antibodies.
Patent Information
- Application Number
- CN202410081646.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-01-19
- Publication Date
- 2024-11-19
- Estimated Expiration
- 2044-01-19
AI Technical Summary
The prior art only targeting B cells in the treatment of systemic lupus erythematosus (SLE) failed to meet the clinical needs. Overproliferation and activation of T cells are also core factors of the disease, and γ-chain cytokines are significantly upregulated in the disease. Antibodies have strong immunogenicity, which can easily lead to the body's production of anti-antibodies and weaken the efficacy.
Develop humanized anti-human CD132 monoclonal antibodies h2D4H4K12 and h5H10H6K4, which reduces the activity of γ-chain cytokines such as IL-21 and IL-4, and combines HEK293 cell expression and purification technology to reduce the immunity of antibodies. Agent, improves efficacy.
This antibody can significantly inhibit the activity of B cells, T cells and NK cells, reduce the level of urinary protein and plasma anti-dsDNA, improve the survival rate of mice, reduce immunogenicity, and enhance the therapeutic effect on SLE.
Smart Images

Figure CN117886940B_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of biomedicine, and specifically relates to a humanized anti-human CD132 monoclonal antibody and an application thereof. Background Art
[0002] CD132 (IL2Rγ), the γ subunit of the interleukin-2 (IL-2) receptor, is also the γ subunit of the following six cytokine receptor complexes: IL2, IL-4, IL-7, IL-9, IL-15, IL-21. Therefore, it is also called γc (common γ chain). Systemic lupus erythematosus (SLE) is a chronic autoimmune disease involving multiple organs and systems. The etiology and pathogenesis are complex and are related to the destruction of autoimmune tolerance, but the exact etiology and specific pathogenesis are still unclear. Among them, B cell dysfunction and the deposition of autoantibodies in the patient's body to form immune complexes are the key reasons for the occurrence and development of SLE. Targeting B cells to treat SLE is a research focus at home and abroad, including Belimumab monoclonal antibody targeting blys, which has been approved for the treatment of lupus erythematosus, and Telitacicept, a fusion protein that can simultaneously target blys and april. However, in addition to B cell disorders, T cell overproliferation and activation are also core factors in SLE pathology. Therefore, targeting B cells alone does not meet the needs of clinical treatment of SLE. + Follicular helper T cells (Tfh) and peripheral helper T cell populations (Th1, Th2, Th17, Treg) mediate B cell activation and autoantibody production by providing co-stimulatory signals and cytokines. Therefore, some T cell-related cytokines have attracted much attention due to their role in promoting inflammation and organ damage in SLE, becoming promising therapeutic targets.
[0003] Many papers have shown that IL4, IL-7, IL9, IL-15 and IL-21 in the γ-chain family of cytokines are significantly upregulated in immune cells of SLE, and these γ-chain cytokines play a key regulatory role in the survival, proliferation and differentiation of various lymphocytes. Given that SLE is a complex disease involving multiple cells and multiple factors, and that the key regulatory role of γ-chain cytokines in various lymphocytes is closely related to the occurrence and development of SLE, intervening in the functional activity of CD132 in γ-chain cytokines may become a potential SLE treatment. Summary of the invention
[0004] The technical problem to be solved by the present invention is to provide a humanized anti-human CD132 monoclonal antibody in view of the deficiencies in the prior art.
[0005] In order to solve the above technical problems, the technical solution adopted by the present invention is as follows:
[0006] A humanized anti-human CD132 monoclonal antibody, wherein the monoclonal antibody is a humanized monoclonal antibody,
[0007] The monoclonal antibody comprises a light chain complementary determining region and a heavy chain complementary determining region, wherein the light chain complementary determining region comprises LCDR1, LCDR2 and LCDR3, and the heavy chain complementary determining region comprises HCDR1, HCDR2 and HCDR3;
[0008] Specifically, the light chain complementary determining region and the heavy chain complementary determining region are selected from any one of the following groups:
[0009] Group 1: The amino acid sequences of LCDR1, LCDR2 and LCDR3 are shown in SEQ ID NOs. 18, 14 and 15, respectively; the amino acid sequences of HCDR1, HCDR2 and HCDR3 are shown in SEQ ID NOs. 3, 4 and 5, respectively;
[0010] or,
[0011] The second group: the amino acid sequences of LCDR1, LCDR2 and LCDR3 are shown in SEQ ID NOs. 26, 27 and 28 respectively; the amino acid sequences of HCDR1, HCDR2 and HCDR3 are shown in SEQ ID NOs. 8, 9 and 10 respectively.
[0012] Wherein, the monoclonal antibody comprises a light chain variable region and a heavy chain variable region, and the light chain variable region and the heavy chain variable region are selected from any one of the following groups:
[0013] Group 1: The amino acid sequence of the light chain variable region is shown in SEQ ID NO.22; the amino acid sequence of the heavy chain variable region is shown in SEQ ID NO.1;
[0014] or,
[0015] The second group: the amino acid sequence of the light chain variable region is shown in SEQ ID NO.29; the amino acid sequence of the heavy chain variable region is shown in SEQ ID NO.6.
[0016] Wherein, the monoclonal antibody further comprises a constant region, and the constant region is the kappa chain constant region Ckappa and the human IgG4 constant region CH1-CH3.
[0017] The present invention also provides a nucleic acid molecule, specifically, a nucleotide sequence encoding the above monoclonal antibody.
[0018] The present invention also provides an expression vector, specifically, comprising the above nucleic acid molecule.
[0019] The present invention also provides a host cell, specifically, comprising the above expression vector.
[0020] Wherein, the host cell is HEK293 cell.
[0021] The present invention also provides a detection reagent or a test kit, characterized in that it comprises the monoclonal antibodies h2D4H4K12 and / or h5H10H6K4.
[0022] The use of the above monoclonal antibody in the preparation of a drug for inhibiting or reducing the activity of human CD132 is also within the scope of protection of the present invention.
[0023] Specifically, in some embodiments, in an in vitro activity experiment to detect the inhibitory activity of humanized candidate antibodies on CD132, the humanized anti-human CD132 antibody h2D4H4K12 can inhibit the activity of IL-21 stimulating NK92 cells to release IFN-γ; the humanized anti-human CD132 antibody h5H10H6K4 can inhibit the activity of IL-4 stimulating Ramos cells to express CD23.
[0024] Specifically, in some embodiments, the antibody h2D4H4K12 or h5H10H6K4 is subcutaneously administered to C57BL / 6 background mice (C57BL / 6 background mice from the Biocytogen breeding colony that have been genetically modified to replace the endogenous CD132 full-length domain with the corresponding human sequence) at a dose of 8 mg / kg or 16 mg / kg, once every 4 days, for 3 consecutive times, and the absolute numbers and ratios of total immune cells, B cells, T cells, NK cells, neutrophils, monocytes, erythrocytes and platelets in the peripheral blood at different time points (once every 10 days) are analyzed by flow cytometry to evaluate the effects of h2D4H4K12 and h5H10H6K4 antibodies on the absolute numbers of these cell types. The results showed that h2D4H4K12 and h5H10H6K4 antibodies had varying degrees of inhibitory effects on B cells, T cells and NK cells, but did not affect the number of neutrophils, monocytes, red blood cells and platelets.
[0025] The use of the above monoclonal antibodies in the preparation of therapeutic drugs for preventing, neutralizing or treating autoimmune diseases is also within the scope of protection of the present invention.
[0026] The autoimmune disease is an immune disease associated with IL-4, IL-7, IL-9, IL-15 and / or IL-21 cytokine receptors, including systemic lupus erythematosus, rheumatoid arthritis, etc.
[0027] Specifically, in some embodiments, pristane (MCE) 0.5 mL was injected into the peritoneal cavity of C57BL / 6 background mice (C57BL / 6 background mice genetically modified from the Biocytogen breeding colony to replace the endogenous CD132 full-length domain with the corresponding human sequence), and the control group was injected with an equal volume of PBS buffer (pH 7.2). h2D4H4K12 or h5H10H6K4 or anti KLH isotype control (all antibodies are produced by Conoya Biotechnology Co., Ltd.) was administered subcutaneously at a dose of 20 mg / kg 3 days before modeling, with a frequency of 2 times a week for 6 weeks, or no administration (Table 5). The levels of urine protein, urine creatinine, and plasma anti-dsDNA in mice were monitored. It was found that h2D4H4K12 and h5H10H6K4 antibodies could significantly reduce the urine protein and plasma anti-dsDNA levels of pristane-induced lupus mice and improve the survival rate of mice.
[0028] Beneficial effects:
[0029] The present invention humanizes two antibodies (2D4 and 5H10) previously obtained in the laboratory, and then obtains two (h2D4H4K12 and h5H10H6K4) high-affinity monoclonal humanized antibodies that can target human CD132 after screening. The inhibitory activity of these two antibodies on five γc cytokines is consistent with that of the maternal chimeras 2D4 and 5H10, while also reducing the immunogenicity of the maternal chimeras, further reducing the risk that the patient may have an immune response to the antibody. Both antibodies can be used in the prevention, neutralization or treatment of autoimmune diseases (such as rheumatoid arthritis, systemic lupus erythematosus, etc.) associated with IL-4, IL-7, IL-9, IL-15 and / or IL-21 cytokines. The present invention also further illustrates the prospects of these two antibodies in the treatment of systemic lupus erythematosus drugs through a systemic erythema animal model. BRIEF DESCRIPTION OF THE DRAWINGS
[0030] The present invention will be further described in detail below in conjunction with the accompanying drawings and specific embodiments, and the above and / or other advantages of the present invention will become more clear.
[0031] Figure 1 Inhibition of IFN-γ secretion by NK92 cells under constant IL-21 stimulation by the parental chimeric anti-human CD132 antibody 2D4 and multiple humanized 2D4 antibodies.
[0032] Figure 2 The parent chimeric anti-human CD132 antibody 5H10 and multiple humanized 5H10 antibodies inhibited the expression of CD23 by Ramos cells under constant IL-4 stimulation.
[0033] Figure 3 h5H10H6K4 inhibits IL21-stimulated NK92 cells from secreting IFN-γ.
[0034] Figure 4 h2D4H4K12 inhibits IL4-stimulated CD23 expression in Ramos cells.
[0035] Figure 5 h5H10H6K4( Figure 5-1 ) and h2D4H4K12( Figure 5-2 ) inhibits IL21-stimulated NK92 cells from secreting IFN-γ.
[0036] Figure 6 h5H10H6K4( Figure 6-1 ) and h2D4H4K12( Figure 6-2 ) inhibits IL7 stimulation of CD4 + T cell downstream phosphorylation.
[0037] Figure 7 h5H10H6K4( Figure 7-1 ) and h2D4H4K12( Figure 7-2 ) inhibited IL9-stimulated M07E cell proliferation.
[0038] Figure 8 Immunogenicity of h2D4H4K12 and h5H10H6K4.
[0039] Fig. 9 h2D4H4K12 and h5H10H6K4 antibodies against CD132 hu / hu Effects of background mouse T cells (9A), B cells (9B), NK cells (9C), neutrophils (9D), erythrocytes (9E), monocytes (9F), platelets (9G) and Treg cells (9H).
[0040] Fig.10 h2D4H4K12 and h5H10H6K4 antibodies against pristane-induced CD132 hu / hu Anti-dsDNA level (10A) and urine protein / creatinine ratio (10B) in the mouse lupus erythematosus model. DETAILED DESCRIPTION
[0041] The experimental methods described in the following examples are conventional methods unless otherwise specified; the reagents and materials described are commercially available unless otherwise specified.
[0042] In previous studies of our research group, we have obtained monoclonal chimeras 2D4 and 5H10 that can target human CD132 through phage screening (the detailed screening, construction information and sequence information of monoclonal chimeras 2D4 and 5H10 of CD132 have been disclosed in patent CN116970081A), but the chimera-configured antibodies have strong immunogenicity and are prone to cause the body to produce anti-antibodies, thereby weakening the efficacy of the antibodies. Therefore, this patent further humanizes the target antibodies 2D4 and 5H10, reduces the immunogenicity of the chimeras without weakening the antibody activity, and simultaneously verifies the target antibodies (h2D4H4K12 and h5H10H6K4) by in vivo pharmacodynamics to further prove the effectiveness of the two antibodies.
[0043] All experiments were approved and performed in accordance with the guidelines of the Ethics Committee of the Dermatology Hospital, Chinese Academy of Medical Sciences (Institute of Dermatology, Chinese Academy of Medical Sciences).
[0044] Example 1: Humanization of monoclonal antibodies 2D4 and 5H10
[0045] The variable region sequences of monoclonal antibodies 2D4 and 5H10 were compared with human germline antibody sequences to find sequences with high homology for CDR transplantation; then, homology modeling was performed by computer to analyze the framework amino acid sequences of the CDR region and its surroundings to examine their spatial three-dimensional binding mode. By calculating electrostatic forces, van der Waals forces, hydrophilicity and entropy values, the key amino acid individuals in the gene sequences of each positive monoclonal antibody that may interact with CD132 and maintain the spatial framework were analyzed, and on this basis, the reverse mutation sites were designed. The HLA-DR affinity was analyzed and examined to select human germline framework sequences with low immunogenicity. The above humanization modifications were designed and completed by Conoya Biotechnology Co., Ltd.
[0046] A total of 1 heavy chain variable region derivative (h2D4-VH4) and 4 light chain variable region derivatives (h2D4-VL3, h2D4-VL9, h2D4-VL11, h2D4-VL12) were obtained for 2D4; a total of 1 heavy chain variable region derivative (h5H10-VH6) and 2 light chain variable region derivatives (h5H10-VL3, h5H10-VL4) were obtained for 5H10. The sequences of all the light and heavy chain variable region derivatives are shown in Tables 1 and 2. The light chain variable region derivatives were cloned into the pHCT2 vector (purchased from Addgene) containing the human IgGκ light chain constant region and regulatory elements independently developed by Conoya to express the complete IgGκ light chain in mammalian cells. The heavy chain variable region derivatives were cloned into the pHCT1s vector (purchased from Addgene) containing the human IgG4 subtype heavy chain constant region and regulatory elements independently developed by Conoya to express the complete IgG4 subtype heavy chain in mammalian cells. After the plasmids were paired, they were transfected into HEK293 cells (purchased from ATCC) and expressed for 5-6 days. The supernatant was collected and filtered and purified using a protein A column to construct candidate humanized antibodies h2D4H4K3, h2D4H4K9, h2D4H4K11, h2D4H4K12, h5H10H6K4 and h5H10H6K5.
[0047] Table 1 Heavy chain variable region derivative sequences of candidate CD132 humanized antibodies (SEQ ID NO.** omitted before the numbers)
[0048]
[0049] Table 2 Light chain variable region derivative sequences of candidate CD132 humanized antibodies (SEQ ID NO.** omitted before the numbers)
[0050]
[0051] Specifically, the humanized antibody heavy chain variable region derivative sequence is:
[0052] 1) The amino acid sequence of h2D4-VH4 is shown in SEQ ID NO.1, the encoding nucleotide sequence is shown in SEQ ID NO.2, and the CDR1, CDR2 and CDR3 thereof are shown in SEQ ID NO.3, 4 and 5 respectively.
[0053] <------------FR1------------>CDR1<----FR2----->CDR2
[0054] QVQLVQSGAEVKKPGSSVKVSCKTSGFNI EDIYLH WVRQAPGQGLEWMG RIDPANGK
[0055] <-------------FR3-------------->CDR3<---FR4-
[0056] SNYDPKFQ RVTITADTSTSTAYMELSSLRSEDTAVYYCAA LRFFGLDY WGQGTLVT
[0057] -->
[0058] VSS
[0059] Nucleotide sequence
[0060] CAGGTTCAGCTGGTTCAGTCTGGCGCCGAAGTGAAGAAACCTGGCAGCAGCGTGAAGGTGAGCTGCAAGACAAGCGGCTTCAACATCGAGGACATCTACCTGCACTGGGTCCGACAGGCTCCAGGACAGGGACTTGAGTGGATGGGCAGAATCGACCCTGCCAACGGCAAGAGCA ACTACGACCCCAAGTTCCAGGGCAGAGTCACCATCACAGCCGACACCAGCACCAGCACCGCCTACATGGAACTGAGCAGCCTGAGAAGCGAGGACACCGCCGTGTACTACTGTGCCGCTCTGAGATTCTTCGGCCTGGACTACTGGGGCCAGGGAACACTGGTTACCGTGTCTAGT
[0061] 2) The amino acid sequence of h5H10-VH6 is shown in SEQ ID NO.6, the encoding nucleotide sequence is shown in SEQ ID NO.7, and the CDR1, CDR2 and CDR3 thereof are shown in SEQ ID NOs.8, 9 and 10, respectively.
[0062] <------------FR1------------>CDR1<----FR2----->CDR2
[0063] QVQLVQSGAEVKKPGASVKVSCKASGYTF TNYWLG WVRQAPGQGLEWMG DIYPGGGY
[0064] <-------------FR3-------------->CDR3<--FR4
[0065] TNYNEKFQ RVTMTADTSTSTVYMELSSLRSEDTAVYFCAR GDYGSSWFPY QUR
[0066] ---->
[0067] VTVSS
[0068] Nucleotide sequence
[0069] CAGGTTCAGCTGGTTCAGTCTGGCGCCGAAGTGAAGAAACCTGGCGCCTCCGTGAAGGTGAGCTGCAAGGCTAGCGGCTACACCTTCACCAACTACTGGCTCGGCTGGGTCCGACAGGCTCCTGGACAGGGACTGGAATGGATGGGCGACATCTACCCTGGCGGCGGATACACAAACT ACAACGAGAAGTTCCAGGGCAGAGTCACAATGACCGCCGACACCTCTACCAGCACAGTCTACATGGAACTGAGCAGCCTGAGAAGCGAGGATACCGCCGTGTACTTCTGTGCCAGAGGCGACTACGGCTCTAGCTGGTTTCCTTACTGGGGCCAGGGAACCCTGGTCACCGTTTCTTCT
[0070] Specifically, the sequence of the humanized antibody light chain variable region derivative is:
[0071] 3) The amino acid sequence of h2D4-VL3 is shown in SEQ ID NO.11, the encoding nucleotide thereof is shown in SEQ ID NO.12, and the CDR1, CDR2 and CDR3 thereof are shown in SEQ ID NOs.13, 14 and 15 respectively.
[0072] <---------FR1--------->CDR1<-----FR2----->CDR2<-
[0073] DMQMTQSPSSLSASVGDRVTITC SATQSVSYMY WYQQKPGKAPELWIY RTSNLAS GV
[0074] -------------FR3-------------->CDR3<--FR4--->
[0075] PSRFSGSGSGTDYTFTISSLQPEDIATYYC QQWSSNPPT FQGKLEIK
[0076] Nucleotide sequence
[0077] GACATGCAGATGACACAGAGCCCTTCTAGCCTGTCTGCCAGCGTGGGCGACAGAGTGACCATCACATGTAGCGCCACACAGAGCGTGTCCTACATGTACTGGTATCAGCAGAAGCCCGGCAAGGCCCTGAGCTTTGGATCTACAGAACAAGCAACCTG GCCAGCGGCGTGCCCTCTAGATTTTCTGGCTCTGGCAGCGGCACCGACTACACCTTCACAATCTCTAGCCTGCAGCCTGAGGATATCGCCACCTACTACTGCCAGCAGTGGTCTAGCAACCCTCCTACATTCGGCCAGGGCACCAAGCTGGAAATCAAG
[0078] 4) The amino acid sequence of h2D4-VL9 is shown in SEQ ID NO.16, its encoding nucleotide is shown in SEQ ID NO.17, and its CDR1, CDR2 and CDR3 are shown in SEQ ID NO.18, 14 and 15 respectively.
[0079] <---------FR1--------->CDR1<-----FR2----->CDR2<-
[0080] EIVLTQSPATLSLSPGERATLSC RATSSVSYMY WYQQKPGQAPRLLIY RTSNLAS GI
[0081] -------------FR3------------->CDR3<--FR4--->
[0082] PARFSGSGSGTDYTLTISSLEPEDFAVYYC QQWSSNPPT FQGKLEIK
[0083] Nucleotide sequence
[0084] GAGATCGTGCTGACACAGAGCCCTGCCACACTGTCACTGTCTCCAGGCGAGAGAGCCACACTGAGCTGTCGCGCCACCAGCAGCGTGTCCTACATGTACTGGTATCAGCAGAAGCCCGGCCAGGCTCCTCGGCTTCTGATCTACAGAACAAGCAACCTG GCCAGCGGCATCCCCGCTAGATTTTCTGGCTCTGGCAGCGGCACCGACTACACCCTGACAATCTCTAGCCTGGAACCTGAGGACTTCGCCGTGTACTACTGCCAGCAGTGGTCTAGCAACCCTCCTACATTCGGCCAGGGCACCAAGCTGGAAATCAAG
[0085] 5) The amino acid sequence of h2D4-VL11 is shown in SEQ ID NO.19, its encoding nucleotide is shown in SEQ ID NO.20, and its CDR1, CDR2 and CDR3 are shown in SEQ ID NOs.21, 14 and 15 respectively.
[0086] <---------FR1--------->CDR1<-----FR2----->CDR2<-
[0087] DIQMTQSPSSLSASVGDRVTITC QATQSVSYMY WYQQKPGKAPELLIY RTSNLAS GV
[0088] -------------FR3------------->CDR3<--FR4--->
[0089] PSRFSGSGSGTDYTFTISSLQPEDIATYYC QQWSSNPPT FQGKLEIK
[0090] Nucleotide sequence
[0091] GACATCCAGATGACACAGAGCCCTTCTAGCCTGTCTGCCAGCGTGGGCGACAGAGTGACCATCACATGTCAGGCCACACAGAGCGTGTCCTACATGTACTGGTATCAGCAGAAGCCCGGCAAGGCCCTGAGCTTCTGATCTACAGAACAAGCAACCTG GCCAGCGGCGTGCCCTCTAGATTTTCTGGCTCTGGCAGCGGCACCGACTACACCTTCACAATCTCTAGCCTGCAGCCTGAGGATATCGCCACCTACTACTGCCAGCAGTGGTCTAGCAACCCTCCTACATTCGGCCAGGGCACCAAGCTGGAAATCAAG
[0092] 6) The amino acid sequence of h2D4-VL12 is shown in SEQ ID NO.22, its encoding nucleic acid is shown in SEQ ID NO.23, and its CDR1, CDR2 and CDR3 are shown in SEQ ID NOs.18, 14 and 15 respectively.
[0093] <---------FR1--------->CDR1<-----FR2----->CDR2<-
[0094] EIVLTQSPATLSLSPGERATLSC RATSSVSYMY WYQQKPGQAPELLIY RTSNLAS GI
[0095] -------------FR3------------->CDR3<--FR4--->
[0096] PARFSGSGSGTDYTLTISSLEPEDFAVYYC QQWSSNPPT FQGKLEIK
[0097] Nucleotide sequence
[0098] GAGATCGTGCTGACACAGAGCCCTGCCACACTGTCACTGTCTCCAGGCGAGAGAGCCACACTGAGCTGTCGCGCCACCAGCAGCGTGTCCTACATGTACTGGTATCAGCAGAAGCCCGGCCAGGCTCCTGAGCTTCTGATCTACAGAACAAGCAACCTG GCCAGCGGCATCCCCGCTAGATTTTCTGGCTCTGGCAGCGGCACCGACTACACCCTGACAATCTCTAGCCTGGAACCTGAGGACTTCGCCGTGTACTACTGCCAGCAGTGGTCTAGCAACCCTCCTACATTCGGCCAGGGCACCAAGCTGGAAATCAAG
[0099] 7) The amino acid sequence of h5H10-VL3 is shown in SEQ ID NO.24, its encoding nucleotide is shown in SEQ ID NO.25, and its CDR1, CDR2 and CDR3 are shown in SEQ ID NOs.26, 27 and 28 respectively.
[0100] <---------FR1--------->CDR1<-----FR2----->CDR2<-
[0101] DIQMTQSPSSLSASVGDRVTITC RASQSISNNLH WYQQKPGKAPKLLIK YASQSIS G
[0102] -------------FR3------------->CDR3<--FR4--->
[0103] VPSRFSGSGSGTDFTLTISSLQPEDFATYFC QQSDSWLT FQGKV
[0104] Nucleotide sequence
[0105] GACATCCAGATGACACAGAGCCCTTCTAGCCTGTCTGCCAGCGTGGGCGACAGAGTGACCATCACATGTAGAGCCAGCCAGAGCATCAGCAACAACCTGCACTGGTATCAGCAGAAGCCCGGCAAGGCTCCCAAGCTGCTGATTAAGTACGCCAGCCAG TCCATCTCCCGGCGTGCCATCTAGATTCAGCGGCTCTGGCTCTGGCACCGACTTCACCCTGACAATCTCTAGCCTGCAGCCTGAGGACTTCGCTACCTACTTCTGCCAGCAGAGCGACAGCTGGCTGACATTTGGCCAGGGCACCAAGGTGGAAATCAAG
[0106] 8) The amino acid sequence of h5H10-VL4 is shown in SEQ ID NO.29, the encoding nucleotide sequence is shown in SEQ ID NO.30, and the CDR1, CDR2 and CDR3 thereof are shown in SEQ ID NOs.26, 27 and 28, respectively.
[0107] <---------FR1--------->CDR1<-----FR2----->CDR2<-
[0108] DIQMTQSPSSLSASVGDRVTITC RASQSISNNLH WYQQKPGKAPKLLIK YASQSIS G
[0109] ---------------FR3------------->CDR3<--FR4--->
[0110] VPSRFSGSGSGTDFTLTISSLQPEDFATYFC QQSDSYLT FQGKV
[0111] Nucleotide sequence
[0112] GACATCCAGATGACACAGAGCCCTTCTAGCCTGTCTGCCAGCGTGGGCGACAGAGTGACCATCACATGTAGAGCCAGCCAGAGCATCAGCAACAACCTGCACTGGTATCAGCAGAAGCCCGGCAAGGCTCCCAAGCTGCTGATTAAGTACGCCAGCCAG TCCATCTCCGGCGTGCCATCTAGATTCAGCGGCTCTGGCTCTGGCACCGACTTCACCCTGACAATCTCTAGCCTGCAGCCTGAGGACTTCGCTACCTACTTCTGCCAGCAGAGCGACAGCTACCTGACATTTGGCCAGGGCACCAAGGTGGAAATCAAG
[0113] Example 2: In vitro activity assay to detect the inhibitory activity of candidate humanized antibodies against CD132
[0114] In order to further evaluate the activity gap between the candidate humanized antibodies and the parent chimera, the experimental method in patent CN116970081A was referred to. Since the parent chimera 2D4 has a strong inhibitory activity on IL21, the method of IL21 stimulating the NK92 cell line to secrete IFN-γ was used to evaluate the 2D4 candidate humanized antibodies; since the activity gap between the 5H10 candidate humanized antibodies was more significant in the IL4 inhibition experimental system, the method of IL4 stimulating the Ramos cell line to upregulate CD23 was selected to further evaluate the 5H10 candidate humanized antibodies.
[0115] 2.1 Validation of 2D4 humanized anti-human CD132 candidate antibody inhibiting NK92 cell secretion of IFN-γ
[0116] 2 × 10 cells were seeded in a 96-well plate using growth medium (prepared according to the instructions of Pronose, but without IL-2). 4 NK-92 cells (Punosai CL-0530) were added and incubated at 37°C in 5% CO2 for starvation overnight. The next day, each 2D4 humanized anti-human CD132 candidate antibody was diluted in a 3-fold gradient from 400nM to 1.6nM in growth medium (without IL-2), added to NK-92 cells and incubated for 30 minutes. After incubation, 250pM IL-21 was added to NK-92 cells containing different 2D4 humanized anti-human CD132 candidate antibodies. After incubation for 72h at 37°C in 5% CO2, ELISA was used to measure the secretion of IFN-γ.
[0117] Using the human IFN-γ ELISA kit (BD catalog number 555142), the capture antibody was coated at a ratio of 1:250 on a 96-well ELISA plate and incubated overnight at 4°C. The next day, the plate was washed three times with PBS buffer (pH7.2), blocked with 10% FBS at room temperature for 1 hour, and then washed three times with PBS buffer (pH7.2). Then, 100 μl of sample (cell supernatant) and standard were added respectively, incubated at room temperature for 2 hours, and then washed five times with PBS buffer (pH7.2). 5AV-HRP was added to the dilution containing 0.4% detection antibody at a ratio of 1:250. Finally, the plate was incubated at room temperature for 1 hour, washed seven times with PBS buffer (pH7.2), and 100 μl of color development solution (TMB solution, Sigma catalog number T2885) was added. After standing at 37°C for 10 minutes, 50 μl of 2M concentrated sulfuric acid solution was added to terminate the reaction, and the plate was immediately placed in an ELISA reader to read the OD. 450 The value of Figure 1 The results showed that the activity of humanized anti-human CD132 antibody h2D4H4K12 in inhibiting IL-21-stimulated IFN-γ release from NK92 cells was comparable to that of the parental 2D4 chimera.
[0118] 2.2 Validation of 5H10 humanized anti-CD132 candidate antibody inhibiting IL-4-stimulated CD23 expression in Ramos cells
[0119] IL-4 can stimulate Ramos cells to express CD23, so this feature can be used to evaluate the inhibitory effect of 5H10 humanized anti-CD132 candidate antibody on IL-4 signaling. Ramos cell line (ATCC) was cultured in RPMI 1640 complete medium containing 10% FBS at 37°C and 5% CO2, and the cell concentration was controlled to contain 2×10 cells per 1 ml. 5 -2×10 6 Cells were inoculated in 96-well flat-bottom cell culture plates, 100 μl per well. Serial dilutions of each 5H10 humanized anti-CD132 candidate antibody were prepared in RPMI 1640 complete medium, and the antibody was diluted in a 4-fold gradient from 200 nM to 0.003 nM, incubated with cells for 30 minutes, and then 50 μl of IL-4 with a final concentration of 2.67 nM was added, and cultured at 37°C, 5% CO2 for 48 hours.
[0120] The cultured cells were transferred to a U-shaped 96-well cell culture plate, centrifuged at 4°C, 300g for 3 minutes, the supernatant was discarded, and the cells were washed twice with flow cytometry buffer (PBS buffer containing 4% calf serum, pH 7.2), 200 μl per well. Take 50 μl of blocking solution (buffer containing 100 μg / ml hIgG) and add it to the cells, block it in an ice bath for 10 minutes, centrifuge it at 300g for 3 minutes and discard the supernatant, then add 50 μl of anti-human CD23 FITC antibody diluent (BD EBVCS-5) to each well, block it in an ice bath for 20 minutes; centrifuge it at 300g for 3 minutes and discard the supernatant, wash the cells twice with flow cytometry buffer, 200 μl per well; take PI staining solution and add it to the cells, 100 μl per well, put it in an ice bath and avoid light for 5 minutes, centrifuge it at 300g for 3 minutes and discard the supernatant, wash the cells twice with 200 μl of flow cytometry buffer per well, and then resuspend the cells with 100 μl of PBS buffer (pH7.2) per well, read the average fluorescence intensity by flow cytometer, and record the measurement results. The results are as follows Figure 2 As shown, the activity of humanized anti-human CD132 antibody h5H10H6K4 in inhibiting IL-4-stimulated CD23 expression in Ramos cells was comparable to that of the parental 5H10 chimera.
[0121] Example 3: Revalidation of humanized anti-human CD132 antibodies h5H10H6K4 and h2D4H4K12
[0122] In Example 2, the inhibitory activity of candidate humanized antibodies against CD132 was detected by in vitro activity experiments, and two humanized anti-human CD132 antibodies h5H10H6K4 and h2D4H4K12 were screened. This example further verified whether the inhibitory activity of the two antibodies against five γc cytokines was consistent with the maternal chimeras 2D4 and 5H10.
[0123] 3.1 Humanized anti-human CD132 antibody h5H10H6K4 inhibits IL21-stimulated NK92 cells from secreting IFN-γ
[0124] To further evaluate the ability of h5H10H6K4 to block IL-21-stimulated NK92 cells from secreting IFN-γ, the specific experimental steps are detailed in Example 2.1, except that the antibody was replaced with h5H10H6K4. Figure 3 , Figure 3 The results showed that the anti-human CD132 antibody h5H10H6K4 could inhibit the release of IFN-γ from NK92 cells stimulated by IL-21, but Figure 1 Compared with the results of h2D4H4K12, its inhibitory activity was weaker than that of h2D4H4K12.
[0125] 3.2 Humanized anti-human CD132 antibody h2D4H4K12 inhibits IL4-stimulated CD23 expression in Ramos cells
[0126] To further evaluate the ability of h2D4H4K12 to block the secretion and expression of CD23 by Ramos cells stimulated by IL-4, the specific experimental steps are detailed in Example 2.2, except that the antibody was replaced with h2D4H4K12. Figure 4 , Figure 4 It showed that the anti-human CD132 antibody h2D4H4K12 could inhibit the expression of CD23 by Ramos cells stimulated by IL-4.
[0127] 3.3 Humanized anti-human CD132 antibodies h2D4H4K12 and h5H10H6K4 inhibit IL15-stimulated NK92 cells from secreting IFN-γ
[0128] To further evaluate the ability of h2D4H4K12 and h5H10H6K4 to block IL-15-stimulated NK92 cells from secreting IFN-γ, the specific experimental steps are detailed in Example 2.1, using antibodies h5H10H6K4 and h2D4H4K12, respectively, and replacing 250 pM IL-21 with 2.5 nM IL-15. The experimental results are shown in Figure 5-1 As shown in 5-2. Figure 5-1 and Figure 5-2 The results showed that both humanized anti-human CD132 antibodies h5H10H6K4 and h2D4H4K12 could inhibit the release of IFN-γ from NK92 cells stimulated by IL-15, but the inhibitory activity of h5H10H6K4 was weaker than that of h2D4H4K12.
[0129] 3.4 Flow cytometric analysis of STAT phosphorylation in human CD4+ T cells (human PBMC)
[0130] To further evaluate the in vitro properties of humanized anti-human CD132 antibodies h5H10H6K4 and h2D4H4K12, their ability to block IL-7-induced CD4 + The experimental process was the same as that of Example 8 in patent CN116970081A, except that the chimeric anti-human CD132 antibodies 5H10 and 2D4 were replaced with humanized anti-human CD132 antibodies h5H10H6K4 and h2D4H4K12. The experimental results are shown in Figure 6-1 and as shown in 6-2. Figure 6-1 and Figure 6-2 The results showed that anti-human CD132 antibodies h5H10H6K4 and h2D4H4K12 could inhibit STAT5 phosphorylation downstream of IL-7-stimulated human peripheral blood CD4+ cells.
[0131] 3.5 Humanized anti-human CD132 antibodies h2D4H4K12 and h5H10H6K4 inhibit IL-9-stimulated M07E cell proliferation
[0132] The inhibitory activity of humanized anti-human CD132 antibodies h5H10H6K4 and h2D4H4K12 on IL-9 was further evaluated. The experimental process was the same as that of Example 10 in patent CN116970081A, except that chimeric anti-human CD132 antibodies 5H10 and 2D4 were replaced by humanized anti-human CD132 antibodies h5H10H6K4 and h2D4H4K12. The results are as follows: Figure 7 As shown, Figure 7-1 and Figure 7-2 The results showed that humanized anti-human CD132 antibodies h5H10H6K4 and h2D4H4K12 could inhibit the proliferation of M07E cells stimulated by IL-9.
[0133] Example 4: Evaluation of the immunogenicity of humanized anti-human CD132 antibodies h2D4H4K12 and h5H10H6K4
[0134] Sample preparation:
[0135] Under sterile conditions, h2D4H4K12, h5H10H6K4 and KLH (expressed by Conoya) were diluted to 200 μg / mL using X-vivo15 (Shanghai Peiyuan) culture medium and sterilized for later use.
[0136] Determination method:
[0137] Peripheral venous blood was collected from 25 healthy volunteers and PBMCs were collected by Ficoll (Healthcare) centrifugation. The cells were washed once with PBS and counted. The cell density was adjusted to 2.5×10 5 / mL, 100μL was added to a 96-well U-shaped plate (corning). 100μL of the diluted sample was added to the cells and cultured at 37°C and 5% CO2 for 48 hours. KLH was used as a positive control and the well without sample was used as a negative control. The same method was used for determination. 200μL / well of the supernatant was discarded from the 96-well plate, and the flow buffer (PBS + 10% FBS) was washed once, and 100μg / mL of hIgG (Jackson) was added, 50μL per well, and incubated on ice for 30 minutes. 1μL / well was added with FITC anti-human CD4, APC anti-human CD137 (OX40), and PE anti-human CD134 (4-1BB) fluorescent antibodies (all fluorescent antibodies were purchased from Biolegend), incubated on ice for 45 minutes, and 50μL of 5μg / mL PI was added for staining for 5 minutes, and the flow buffer was washed twice, and 100μL PBS was resuspended and analyzed by flow cytometry.
[0138] Data Analysis:
[0139] (1) Lymphocyte gating based on cell size (FSC-A) and granularity (SSC-A);
[0140] (2) In the lymphocyte population, adherent cells were excluded based on FSC-A and FSC-H, and single cell populations were circled;
[0141] (3) Circle the live cell population in the single cell population based on FSC-A and PI light signals;
[0142] (4) Circle the CD4-positive T cells among the living cells and analyze the proportion of CD137 (OX40) and CD134 (4-1BB) double-positive cells in this group of cells.
[0143] The final result is Figure 8 As shown, the double positive cells of humanized anti-human CD132 antibodies h2D4H4K12 and h5H10H6K4 were comparable to the negative control, indicating that the above two antibodies have extremely low immunogenicity.
[0144] Example 5: In vivo immunosuppressive experiment to evaluate the effects of anti-human CD132 antibodies h2D4H4K12 and h5H10H6K4 on immune cell populations in the blood
[0145] Experimental procedure: C57BL / 6 background mice (C57BL / 6 background mice from the Biocytogen breeding colony that were genetically modified to replace the endogenous CD132 full-length domain with the corresponding human sequence) were subcutaneously administered with antibodies h2D4H4K12 or h5H10H6K4 at a dose of 8 mg / kg or 16 mg / kg, once every 4 days for 3 doses, with no administration of antibodies h2D4H4K12 or h5H10H6K4 as a control.
[0146] Table 3 Experimental drug administration and treatment scheme of mice in each group
[0147] Grouping Recipient strain Number of each group Antibody treatment Group A <![CDATA[CD132 hu / hu ]]> 6 h2D4H4K12, 8mg / kg Group B <![CDATA[CD132 hu / hu ]]> 6 h2D4H4K12, 16mg / kg Group C <![CDATA[CD132 hu / hu ]]> 6 h5H10H6K4, 8mg / kg Group D <![CDATA[CD132 hu / hu ]]> 6 h5H10H6K4, 16mg / kg Group E <![CDATA[CD132 hu / hu ]]> 6 Not applied
[0148] Analysis of immune cell populations in the blood over a period of time by flow cytometry. The specific process is as follows: The number of total immune cells, B cells, T cells, NK cells and neutrophils in peripheral blood at different time points (once every 10 days) was analyzed by flow cytometry to evaluate the effect of h2D4H4K12 and h5H10H6K4 antibodies on the absolute number of these cell types. In short, at each time point, blood samples from each mouse were collected, and 50-100 μL of each blood sample was incubated in red blood cell lysis buffer (Biyuntian) at room temperature for 10 minutes to lyse red blood cells. If the lysis is not in place, a second round of lysis is performed. Wash twice in PBS buffer (Shanghai Peiyuan, pH 7.2), and then dilute mouse IgG (Jackson Immunoresearch) to 200 μg / ml with flow buffer (4% FBS (ExCell Bio)) to prepare FC receptor blocking solution. Add 50 μl of blocking solution to each lysed blood sample and block at room temperature for 10 minutes. The cells were then stained for cell surface markers by adding a cocktail of fluorescently labeled antibodies (described in Table 4) diluted in flow buffer to identify CD45 + Cells, T cells, B cells and NK cells (the absolute number of neutrophils, monocytes, red blood cells and platelets were all measured using a mouse blood routine analyzer). Finally, the samples were washed twice in flow cytometry buffer, resuspended in PBS buffer (pH 7.2), and sample data were acquired on a BDcelesta flow cytometer. Data analysis was performed using FlowJov10 software. CD45 + Immune cells were defined as singlet, viable cells, and within this group, T cells were further defined as CD3 + , Treg cells were further defined as CD4 + 、CD25 + , B cells were further defined as CD3 - 、CD19 + NK cells are further defined as CD3 - 、CD19 - 、NK1.1 + .
[0149] Table 4 Antibodies used in flow cytometry analysis
[0150] Antibody Fluorescent Antibodies Manufacturer Final dilution CD45 PE BD 1:400 CD3 APC-Cy7 BD 1:200 CD4 FITC Biolegend 1:200 CD8a BV510 BD 1:200 CD19 APC Biolegend 1:200 CD25 PerCP-Cy5.5 BD 1:200 NK1.1 BV650 BD 1:200
[0151] The results are as follows Fig. 9 As shown: Treatment of background mice with h2D4H4K12 or h5H10H6K4 (8mg / kg and 16mg / kg) resulted in T cells in their blood ( Fig. 9 A) and B cells ( Fig. 9 B) and NK cells ( Fig. 9 C) decreased significantly, while neutrophils ( Fig. 9 D) Red blood cells ( Fig. 9 E), monocytes ( Fig. 9 F), platelet count ( Fig. 9 G) were not affected, among which h2D4H4K12 had no significant effect on the proportion of Treg cells ( Fig. 9 H). After the 3 doses, the serum concentrations of h2D4H4K12 and h5H10H6K4 decreased over time. By the end of the study, all these groups returned to similar levels observed before treatment. These results indicate that both h2D4H4K12 and h5H10H6K4 antibodies have varying degrees of inhibitory effects on B cells, T cells, and NK cells, but do not affect the number of neutrophils, monocytes, red blood cells, and platelets, and that h2D4H4K12 has a weaker inhibitory effect on Treg cells than h5H10H6K4.
[0152] Example 6: Establishment of a pristane-induced mouse lupus erythematosus model for evaluating the blocking activity of anti-human CD132 antibodies h2D4H4K12 and h5H10H6K4.
[0153] Experimental procedure: 0.5 mL of pristane (MCE) was injected into the peritoneal cavity of C57BL / 6 background mice (C57BL / 6 background mice genetically modified from the Biocytogen breeding colony to replace the endogenous CD132 full-length domain with the corresponding human sequence), and the control group was injected with an equal volume of PBS buffer (pH 7.2). h2D4H4K12 or h5H10H6K4 or anti KLH isotype control (all antibodies are produced by Conoya Biotechnology Co., Ltd.) was administered subcutaneously at a dose of 20 mg / kg 3 days before modeling, with a frequency of 2 times a week for 6 weeks, or no administration (Table 5). The levels of mouse urine protein, urine creatinine, and plasma anti-dsDNA were monitored. Mice were killed by cervical dislocation at week 12.
[0154] Specific monitoring experimental steps:
[0155] 1. Use the Mouse Urine Microalbumin ELISA Detection Kit (Elabscience) to detect mouse urine microalbumin: Collect 20μl of each mouse urine and perform the test according to the operating procedures. In short, dilute the urine of each mouse 1000 times with the standard / sample diluent, add 100μl to each well of the 96-well ELISA plate that has been coated in the kit, incubate at 37°C for 90 minutes, dry, add 100μl of biotinylated antibody working solution to each well, and incubate at 37°C for 1 hour. Wash 4 times, add 100μl of HRP enzyme conjugate working solution to each well, incubate at 37°C for 30 minutes, wash 4 times, add 90μl of color development solution, place at 37°C for 10 minutes, then add 50μl of stop solution, and immediately place in the microplate reader to read the OD 450 The value of .
[0156] 2. ELISA detection of anti-dsDNA levels in mouse plasma: Collect 50-100 μl of blood from each mouse, centrifuge at 4500 rpm, and freeze the supernatant at -80°C for subsequent testing. Coat UltraPure at 100 μg / ml on a 96-well ELISA plate. TM Salmon sperm DNA solution (Invitrogen), incubate at 4°C overnight. The next day, wash three times with PBS buffer (pH 7.2), block with 10% BSA (Sangon) at 37°C for 1 hour, wash three times with PBS buffer (pH 7.2), then add 50-fold diluted plasma samples, 100 μl per well, incubate at 37°C for 90 minutes, then wash five times with PBS buffer (pH 7.2), add HRP-labeled Fc-specific anti-mouse IgG1 (abclonal) at a ratio of 1:4000. Incubate at room temperature for 1 hour, wash seven times with PBS buffer (pH 7.2), add 100 μl of colorimetric solution (TMB solution, Sigma catalog number T2885), place at 37°C for 10 minutes, add 50 μl of 2M concentrated sulfuric acid solution to terminate the reaction, and immediately place in an ELISA reader to read the OD 450 The value of .
[0157] Table 5 Experimental drug administration and treatment scheme for each group of mice
[0158] Grouping Recipient strain Number of each group Modeling mAb treatment Group A <![CDATA[CD132 hu / hu ]]> 5 PBS injection No mAb Group B <![CDATA[CD132 hu / hu ]]> 10 Injection of pristane anti KL(isotype) Group C <![CDATA[CD132 hu / hu ]]> 10 Injection of pristane h2D4H4K12 Group D <![CDATA[CD132 hu / hu ]]> 10 Injection of pristane h5H10H6K4
[0159] The results are as follows Fig.10 As shown: h2D4H4K12 or h5H10H6K4 antibodies can reduce the level of autoantibodies anti-dsDNA in mouse plasma ( Fig.10 A) Reduce the urine protein / creatinine ratio of mice ( Fig.10B). This indicates that h2D4H4K12 and h5H10H6K4 antibodies can significantly reduce urine protein and plasma anti-dsDNA levels in pristane-induced lupus mice and improve the survival rate of mice.
[0160] In summary, the above in vitro and in vivo experiments have shown that humanized anti-human CD132 antibodies h2D4H4K12 and h5H10H6K4 can inhibit the activity of IL4, IL-7, IL9, IL-15 and / or IL-21, and further experiments on lupus erythematosus model mice have found that both antibodies can significantly improve the phenotype of lupus erythematosus model mice. Therefore, these two antibodies may have potential value in treating autoimmune diseases with the above cytokine secretion as an important pathophysiological change.
[0161] The present invention provides a humanized anti-human CD132 monoclonal antibody and its application ideas and methods. There are many methods and ways to implement the technical solution. The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, without departing from the principle of the present invention, several improvements and modifications can be made, and these improvements and modifications should also be regarded as the scope of protection of the present invention. All components not specified in this embodiment can be implemented by existing technologies.
Claims
1. A humanized anti-human CD132 monoclonal antibody, characterized in that: The monoclonal antibody is a humanized monoclonal antibody, The monoclonal antibody comprises a light chain complementary determining region and a heavy chain complementary determining region, wherein the light chain complementary determining region comprises LCDR1, LCDR2 and LCDR3, and the heavy chain complementary determining region comprises HCDR1, HCDR2 and HCDR3; The light chain complementary determining region and heavy chain complementary determining region are as follows: The amino acid sequences of LCDR1, LCDR2 and LCDR3 are shown in SEQ ID NOs. 18, 14 and 15, respectively; the amino acid sequences of HCDR1, HCDR2 and HCDR3 are shown in SEQ ID NOs. 3, 4 and 5, respectively.
2. The monoclonal antibody according to claim 1, characterized in that The monoclonal antibody comprises a light chain variable region and a heavy chain variable region, and the light chain variable region and the heavy chain variable region are as follows: The amino acid sequence of the light chain variable region is shown in SEQ ID NO.22; the amino acid sequence of the heavy chain variable region is shown in SEQ ID NO.
1.
3. The monoclonal antibody according to claim 1, characterized in that The monoclonal antibody further comprises a constant region, which is a kappa chain constant region Ckappa and a human IgG4 constant region CH1-CH3.
4. A nucleic acid molecule, characterized in that Encodes the monoclonal antibody according to any one of claims 1 to 3.
5. An expression vector, characterized in that: Comprising the nucleic acid molecule of claim 4.
6. A host cell, characterized in that Comprising the expression vector according to claim 5.
7. The host cell according to claim 6, characterized in that The host cell is HEK293 cell.
8. A detection reagent or kit, characterized in that: It contains the monoclonal antibody according to any one of claims 1 to 3.
9. Use of the monoclonal antibody according to any one of claims 1 to 3 in the preparation of a medicament for treating autoimmune diseases; in, The autoimmune disease is rheumatoid arthritis or systemic lupus erythematosus.
